A Medical Device Daily

Cytori Therapeutics (San Diego) reported receiving two notices of allowance from the U.S. Patent & Trademark Office for patents covering methods related to the Celution system output. The allowances add commercial applications to U.S. Patent No. 7,390,484, issued in June 2008, which covers the Celution system, Cytori said.

The system processes adipose-derived stem and regenerative cells at a patient's bedside. The allowances will provide significant added protection for formulations and applications of the Celution system output, the company said.

One patent allowance covers methods for cooling and cryopreserving the Celution system output (i.e., adipose-derived stem and regenerative cells) relevant to the company's cell banking platform. Currently, Cytori is manufacturing its Celution system in the U.S. to be sold as part its StemSource business, a cell banking product offered in Europe, Asia and other international markets.

The second allowance covers methods to combine the Celution system output with additives such as scaffolds, matrices or other agents to increase therapeutic effect, optimize or localize cell delivery, enhance specific cell properties or promote cell differentiation.

Cytori says it is developing new options for reconstructive surgery and treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells.